Adjuncts for ovarian stimulation: when do we adopt "orphan indications" for approved drugs?

David R. Meldrum, R. Jeffrey Chang, Dominique de Ziegler, William B. Schoolcraft, Richard T. Scott, Antonio Pellicer, António Pellicer
Fertility and sterility · 2009 · vol. 92(1) , pp. 13–18 · doi:10.1016/j.fertnstert.2009.03.081 · PMID:19423104 · W2152736272
Review OA: bronze CC0
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-09 ⓘ

The authors evaluate the efficacy and safety of approved drugs used as adjuncts for ovarian stimulation under orphan indications, providing recommendations to expand their clinical utility.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Several drugs, shown to be safe for other uses, have proven to be highly effective adjuncts for ovarian stimulation. The authors evaluate these "orphan" indications and make recommendations so that more patients will benefit from their use.

My notes (saved in your browser only)

MeSH descriptors

Orphan Drug Production Ovulation Induction Polycystic Ovary Syndrome Androgens Androgens Aspirin Aspirin Contraceptives, Oral Contraceptives, Oral Dopamine Agonists Dopamine Agonists Estrogens Estrogens Female Fertilization in Vitro Fertilization in Vitro Human Growth Hormone Human Growth Hormone Humans Leuprolide

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (51)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:06:23.467768+00:00
License: CC0 · commercial use OK